Abstract

The MA Holder shall design and conduct a Phase Ib Clinical Trial with route, escalating doses and varying schedule of administation, using Interleukin-2 (IL-2) alone or (IL-2) with adoptive transfer of cytotoxic cells.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM047666-001003
Application #
3612095
Study Section
Project Start
1987-09-30
Project End
Budget Start
1990-06-29
Budget End
1991-05-31
Support Year
Fiscal Year
1990
Total Cost
Indirect Cost

  Institution

Name
Ohio State University
Department
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210

  Publications

Kim, J A; Dayton, M A; Aldrich, W et al. (1999) Modulation of CD4 cell cytokine production by colon cancer-associated mucin. Cancer Immunol Immunother 48:525-32
Doran, T; Stuhlmiller, H; Kim, J A et al. (1997) Oncogene and cytokine expression of human colorectal tumors responding to immunotherapy. J Immunother 20:372-6
Triozzi, P L; Tucker, F; Benzies, T et al. (1996) Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor. Bone Marrow Transplant 18:47-52
Triozzi, P L; Kim, J A; Martin, E W et al. (1995) Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2. J Clin Oncol 13:482-9
Triozzi, P L; Aldrich, W; Kim, J et al. (1994) Biologic effects of the adoptive transfer of cells depleted of monocytes with L-phenylalanine methyl ester. Immunopharmacology 28:39-45
Triozzi, P L; Eicher, D M; Rinehart, J J (1992) Modulation of adhesion molecules on human large granular lymphocytes by interleukin-2 in vivo and in vitro. Cell Immunol 140:295-303
Sagone Jr, A L; Husney, R M; Triozzi, P L et al. (1991) Interleukin-2 therapy enhances salicylate oxidation by blood granulocytes. Blood 78:2931-6